Controlled striatal DOPA production from a gene delivery system in a rodent model of parkinson's disease

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 896-906

  Cederfjäll, Erik ^a   Broom, Lauren ^a   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DIHYDROFOLATE REDUCTASE; DOPA; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HOMOVANILLIC ACID; TRIMETHOPRIM; BIOLOGICAL MARKER; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; RODENT MODEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; CELL LINE; CLASSIFICATION; CORPUS STRIATUM; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; PHENOTYPE; SEROTYPE; TRANSGENE;

RODENTIA;

ANIMALS; BEHAVIOR, ANIMAL; BIOMARKERS; CELL LINE; CORPUS STRIATUM; DEPENDOVIRUS; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GTP CYCLOHYDROLASE; HUMANS; PARKINSON DISEASE; PHENOTYPE; RATS; SEROGROUP; TETRAHYDROFOLATE DEHYDROGENASE; TRANSDUCTION, GENETIC; TRANSGENES; TRIMETHOPRIM; TYROSINE 3-MONOOXYGENASE;

EID: 84929049610     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.8     Document Type: Article

References (43)

1. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al. (2014). Long-term safety and tolerability of ProSavin a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation open-label phase ' trial. Lancet 383: 1138-1146
2. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, et al. (2013). Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80: 1698-1701
3. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind sham-surgery controlled randomised trial. Lancet Neurol 10: 309-319
4. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. (2010). Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind randomised controlled trial. Lancet Neurol 9: 1164-1172
5. Muramatsu S-I, Fujimoto K-I, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. (2010). A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18: 1731-1735
6. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73: 1662-1669
7. Sage JI, Trooskin S, Sonsalla PK and Heikkila RE. (1989). Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease. Neurology 39(11 Suppl 2): 60-3; discussion 72
8. Sage JI, Trooskin S, Sonsalla PK, Heikkila R and Duvoisin RC. (1988). Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24: 87-89
9. Mouradian MM, Juncos JL, Fabbrini G and Chase TN. (1987). Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 22: 475-479
10. Shoulson I, Glaubiger GA and Chase TN. (1975). On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144-1148
11. Cederfjäll E, Sahin G and Kirik D. (2012). Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiol Dis 48: 222-227
12. Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, et al. (2005). Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain 128(Pt 3): 559-569
13. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, et al. (2002). Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 99: 4708-4713
14. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK and Leff SE. (1998). Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 18: 4271-4284
15. Kang UJ, Park DH, Wessel T, Baker H and Joh TH. (1992). Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions. Neurosci Lett 147: 53-57
16. Hökfelt T, Fuxe K and Goldstein M. (1973). Immunohistochemical localization of aromatic L-amino acid decarboxylase (DOPA decarboxylase) in central dopamine and 5-hydroxytryptamine nerve cell bodies of the rat. Brain Res 53: 175-180
17. Björklund T, Carlsson T, Cederfjäll EA, Carta M and Kirik D. (2010). Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain 133(Pt 2): 496-511
18. Cederfjäll E, Sahin G, Kirik D and Björklund T. (2012). Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Mol Ther 20: 1315-1326
19. Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG and Wandless TJ. (2006). A rapid reversible and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126: 995-1004
20. Iwamoto M, Björklund T, Lundberg C, Kirik D and Wandless TJ. (2010). A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol 17: 981-988
21. Tai K, Quintino L, Isaksson C, Gussing F and Lundberg C. (2012). Destabilizing domains mediate reversible transgene expression in the brain. PLoS One 7: e46269
22. Cederfjäll E, Nilsson N, Sahin G, Chu Y, Nikitidou E, Björklund T, et al. (2013). Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep 3: 2157
23. Manfredsson FP, Bloom DC and Mandel RJ. (2012). Regulated protein expression for in vivo gene therapy for neurological disorders: progress strategies and issues. Neurobiol Dis 48: 212-221
24. Gossen M and Bujard H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551
25. Mansuy IM and Bujard H. (2000). Tetracycline-regulated gene expression in the brain. Curr Opin Neurobiol 10: 593-596
26. Stieger K, Belbellaa B, Le Guiner C, Moullier P and Rolling F. (2009). In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 61: 527-541
27. Corti O, Sánchez-Capelo A, Colin P, Hanoun N, Hamon M and Mallet J. (1999). Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci USA 96: 12120-12125
28. Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D and Lundberg C. (2004). Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum using a tetracycline-dependent lentiviral vector. Hum Gene Ther 15: 934-944
29. Manfredsson FP, Burger C, Rising AC, Zuobi-Hasona K, Sullivan LF, Lewin AS, et al. (2009). Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 17: 1857-1867
30. Han Y, Chang QA, Virag T, West NC, George D, Castro MG, et al. (2010). Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors. Gene Ther 17: 616-625
31. Xu, F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296: 964-973
32. Sullins AK and Abdel-Rahman SM. (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs 15: 93-117
33. Xie J, Nair A and Hermiston TW. (2008). A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types. Toxicol In Vitro 22: 261-266
34. Sando R 3rd, Baumgaertel K, Pieraut S, Torabi-Rander N, Wandless TJ, Mayford M, et al. (2013). Inducible control of gene expression with destabilized Cre. Nat Methods 10: 1085-1088
35. Mouradian MM, Heuser IJ, Baronti F and Chase TN. (1990). Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27: 18-23
36. Watson C and Paxinos G. The Rat Brain in Stereotaxic Coordinates. Academic Press San Diego CA, 1986
37. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985
38. Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I, et al. (2012). Universal real-time PCR for the detection and quantification of adenoassociated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods 23: 18-28
39. Dowd E, Monville C, Torres EM and Dunnett SB. (2005). The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 68: 24-30
40. Schallert T, De Ryck M, Whishaw IQ, Ramirez VD and Teitelbaum P. (1979). Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp Neurol 64: 33-43
41. Olsson M, Nikkhah G, Bentlage C and Björklund A. (1995). Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15(5 Pt 2): 3863-3875
42. Gundersen HJ and Jensen EB. (1987). The efficiency of systematic sampling in stereology and its prediction. J Microsc 147(Pt 3): 229-263
43. West, MJ. (1999). Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 22: 51-61